The Landscape of Chemoprevention in Lung Cancer: A Conversation With Waun K. Hong, MD, PhD
Over the past 25 years, multiple lung cancer chemoprevention trials have missed the mark with agents that looked good on paper but lacked the molecular biology support to make a difference.
ASCO GI Coverage: Delaying Chemotherapy Increases the Mortality Risk of Patients with Colon Cancer
The results of a systematic review and meta-analysis suggest that the mortality risk for colon cancer patients begins to increase with any avoidable delay in adjuvant chemotherapy beyond 4 weeks.
ASCO GI Coverage: Everolimus Associated With Significant PFS Improvement in Patients With PNETs
Data from a large randomized trial showed that treatment with the targeted agent everolimus was associated with a 65% improvement in progression-free survival (PFS) in patients with advanced pancreatic neuroendocrine tumors (PNETs).
ASCO GI Coverage: Women Who Use Bisphosphonates for Osteoporosis Reduce Their Risk of Colorectal Cancer
The risk of colorectal cancer declined by 33% among postmenopausal women taking oral bisphosphonates for osteoporosis
ASCO GI Coverage: Australian Study Finds ISH to Be the Best Assessor of HER2 Expression in Gastric Cancer
In situ hybridization (ISH) yields the best results for assessing HER2 expression in gastric cancer, according to a multilaboratory analysis of testing methods.
ASCO GI Coverage: Study Finds Tumor Characteristics Correlate With Survival in Stomach, Esophageal Cancers
An analysis of the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) database showed that advanced gastric or esophageal cancer confers a poor prognosis
ASCO GI Coverage: Imatinib Trough Levels Remain Stable in Most Advanced GIST Patients During Long-Term Treatment
Patients with gastrointestinal stromal tumors (GIST) had stable plasma concentrations of imatinib during long-term treatment, reported Yoon-Koo Kang, MD, PhD, and colleagues at the Gastrointestinal Cancers Symposium.
ASCO GI Coverage: European Study Shows Bevacizumab to Be Ineffective as Adjuvant Therapy
The results of a large, multicenter trial showed that the addition of bevacizumab to adjuvant chemotherapy failed to improve disease-free survival (DFS) compared with chemotherapy alone.
ASCO GI Interview Series: Robert Rosenberg, MD, Discusses Advantages of ColoPrint Test
At the 2011 symposium in San Francisco, California, Oncology & Biotech News spoke with the author of one of the featured presentations at the meeting
ASCO GI Interview Series: Improving Patient Outcomes in Pancreatic Cancer: A Conversation with Mitchell C. Posner, MD
Few cancers have a bleaker outlook than pancreatic cancer.
Benefit of Elacestrant Improves With Longer Duration of CDK4/6 Inhibition in Patients With ER+/HER2– Metastatic Breast Cancer
Lifileucel Induces Response in Metastatic Melanoma Independent of Number of IL-2 Doses Received
Rajkumar Previews CAR-T Updates, Elranatamab Findings in Multiple Myeloma Ahead of ASH 2022
Palbociclib Plus Fulvestrant Fails to Improve PFS in ER+/HER2- Breast Cancer After Progression on a CDK4/6 inhibitor
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.